Summary & Overview
HCPCS J2720: Protamine Sulfate Injection, per 10 mg
HCPCS Level II code J2720 designates the injection of protamine sulfate per 10 mg, a critical antidote used to reverse heparin anticoagulation. Nationally, this code matters because timely and accurate billing for reversal agents affects hospital reimbursement, medication cost accounting, and acute care workflows for procedures and emergencies where heparin reversal is required. The code captures a discrete pharmacologic service frequently provided in inpatient, outpatient procedural, and emergency settings.
Key payers addressed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for protamine sulfate use, common sites of service where the drug is administered, and the billing implications of per-unit coding for inventory and charge capture. The publication summarizes typical payer coverage patterns, benchmark considerations for per-dose billing, and operational notes relevant to hospital and emergency department providers.
This report provides actionable reference material on coding scope, national relevance, and what to expect in payer treatment of protamine sulfate administration under J2720. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code J2720 describes an injection of protamine sulfate, billed per 10 mg. This code represents the pharmaceutical administration of protamine sulfate, an agent used to reverse the anticoagulant effects of heparin.
Service type: Drug administration / antidote reversal
Typical site of service: Hospital inpatient or outpatient settings, emergency department, or other acute care settings where intravenous drug reversal is required.
Clinical & Coding Specifications
Clinical Context
A patient on therapeutic anticoagulation (for example, receiving unfractionated heparin infusion after cardiac surgery or for treatment of a pulmonary embolism) develops excessive bleeding or requires rapid reversal of heparin effect for an urgent invasive procedure. Protamine sulfate J2720 is administered by intravenous injection to neutralize circulating heparin. Typical workflow: assessment of bleeding risk and heparin dosing, verification of last heparin dose and coagulation studies (e.g., activated partial thromboplastin time), informed consent when indicated, preparation of protamine sulfate dose (commonly calculated as 1 mg protamine per 100 units of unfractionated heparin given within the prior 2–3 hours, not to exceed institutional maximums), slow IV administration with monitoring for hypotension, bradycardia, and allergic/anaphylactoid reactions, repeat coagulation testing to confirm reversal, and documentation of amount administered using billing code J2720 per 10 mg increment. Typical site of service: inpatient hospital (ICU, operating room, post-anesthesia care unit), emergency department, or procedural suite. Typical patient scenario: a postoperative cardiac surgery patient with prolonged bleeding after cardiopulmonary bypass who requires protamine reversal of residual heparin, or a medical patient on heparin with acute gastrointestinal hemorrhage requiring rapid neutralization of anticoagulation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|